The Upper Airway as the Primary Point of Intervention in Respiratory Virus Protection

The Upper Airway as the Primary Point of Intervention in Respiratory Virus Protection

The Site of Initial Viral Exposure

The nasal cavity and upper airway are where respiratory viruses first make contact with the human body. Initial viral replication begins here. Early host responses are first activated here. The course of infection is substantially influenced by what happens in this early window.

Intervening at this site, before viral replication becomes established, provides an opportunity that downstream therapeutic approaches cannot access. Vaccines are preparatory and pathogen-specific. Antivirals address infection that has already occurred. Neither operates at the point of entry, in the window between first exposure and established infection.

A Host-Directed Approach

Rather than targeting a specific virus or pathogen, a host-directed approach activates the body's own innate antiviral defences at the site of exposure. The innate immune system responds to the signatures of viral infection rather than to a specific pathogen identity. By working through this system, an intervention can offer protection that is not constrained by which virus is circulating.

This is the principle underlying N001, Ness Therapeutics Inc.'s lead program. N001 is a self-administered intranasal prophylactic designed to activate innate antiviral defences directly at the upper airway, for prevention and early post-exposure use across known and emerging respiratory virus threats.

The Evidence

The rationale for N001 is supported by a body of preclinical and clinical work showing broad antiviral protection, reduced lung disease severity, accelerated viral clearance, and reduced inflammatory biomarkers. A household randomized clinical trial involving 1,172 participants across 341 households also demonstrated a transmission signal, with lower viral burden observed in exposed contacts.

Together, these findings provide a strong translational basis for advancing an airway-focused prophylactic toward clinical readiness.

Where the Program Stands

N001 is currently in IND/CTA-enabling development, supported by funding from the Government of Canada and in partnership with the National Research Council of Canada. The program is advancing through formulation development, preclinical safety and efficacy studies, toxicology, and regulatory preparation, with the objective of achieving first-in-human study and advancement toward a Phase 2-ready asset.

To follow the program's progress or explore investment opportunities, visit www.nesstherapeuticsinc.com/contact-us.